Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Investigation  of  dose-dependent  effects  of  fat  on  blood glucose,  serum  insulin,  and  appetite  sensation.

Yamaguchi C, Yamanaka-Okumura H, Esumi H, Masuda M, Katayama T, Taketani Y.

J Med Invest. 2018;65(3.4):203-207. doi: 10.2152/jmi.65.203.

2.

Sucrose nonfermenting AMPK-related kinase (SNARK) regulates exercise-stimulated and ischemia-stimulated glucose transport in the heart.

Sun XL, Lessard SJ, An D, Koh HJ, Esumi H, Hirshman MF, Goodyear LJ.

J Cell Biochem. 2019 Jan;120(1):685-696. doi: 10.1002/jcb.27425. Epub 2018 Sep 7.

PMID:
30256437
3.

Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.

Fujioka R, Mochizuki N, Ikeda M, Sato A, Nomura S, Owada S, Yomoda S, Tsuchihara K, Kishino S, Esumi H.

PLoS One. 2018 Jun 1;13(6):e0198219. doi: 10.1371/journal.pone.0198219. eCollection 2018.

4.

Thymidine catabolism promotes NADPH oxidase-derived reactive oxygen species (ROS) signalling in KB and yumoto cells.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Toyoda Y, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI.

Sci Rep. 2018 Apr 30;8(1):6760. doi: 10.1038/s41598-018-25189-y.

5.

Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress.

Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M, Esumi H, Murray GI, Sansom OJ, Zanivan SR, Murphy DJ.

Cancer Discov. 2018 May;8(5):632-647. doi: 10.1158/2159-8290.CD-17-0533. Epub 2018 Mar 2.

6.

Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.

Makinoshima H, Umemura S, Suzuki A, Nakanishi H, Maruyama A, Udagawa H, Mimaki S, Matsumoto S, Niho S, Ishii G, Tsuboi M, Ochiai A, Esumi H, Sasaki T, Goto K, Tsuchihara K.

Cancer Res. 2018 May 1;78(9):2179-2190. doi: 10.1158/0008-5472.CAN-17-2109. Epub 2018 Feb 28.

7.

Oncogenic Kit signalling on the Golgi is suppressed by blocking secretory trafficking with M-COPA in gastrointestinal stromal tumours.

Obata Y, Horikawa K, Shiina I, Takahashi T, Murata T, Tasaki Y, Suzuki K, Yonekura K, Esumi H, Nishida T, Abe R.

Cancer Lett. 2018 Feb 28;415:1-10. doi: 10.1016/j.canlet.2017.11.032. Epub 2017 Nov 28.

8.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

9.

Thymidine Catabolism as a Metabolic Strategy for Cancer Survival.

Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI.

Cell Rep. 2017 May 16;19(7):1313-1321. doi: 10.1016/j.celrep.2017.04.061.

10.

Highly oxygenated antiausterity agents from the leaves of Uvaria dac.

Awale S, Tawila AM, Dibwe DF, Ueda JY, Sun S, Athikomkulchai S, Balachandran C, Saiki I, Matsumoto K, Esumi H.

Bioorg Med Chem Lett. 2017 May 1;27(9):1967-1971. doi: 10.1016/j.bmcl.2017.03.021. Epub 2017 Mar 11.

PMID:
28342587
11.

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors.

Obata Y, Horikawa K, Takahashi T, Akieda Y, Tsujimoto M, Fletcher JA, Esumi H, Nishida T, Abe R.

Oncogene. 2017 Jun 29;36(26):3661-3672. doi: 10.1038/onc.2016.519. Epub 2017 Feb 13.

12.

Constituents of the Rhizomes of Boesenbergia pandurata and Their Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Line.

Nguyen NT, Nguyen MT, Nguyen HX, Dang PH, Dibwe DF, Esumi H, Awale S.

J Nat Prod. 2017 Jan 27;80(1):141-148. doi: 10.1021/acs.jnatprod.6b00784. Epub 2017 Jan 18.

PMID:
28099006
13.

Development of Highly Selective Fluorescent Probe Enabling Flow-Cytometric Isolation of ALDH3A1-Positive Viable Cells.

Yagishita A, Ueno T, Esumi H, Saya H, Kaneko K, Tsuchihara K, Urano Y.

Bioconjug Chem. 2017 Feb 15;28(2):302-306. doi: 10.1021/acs.bioconjchem.6b00618. Epub 2016 Dec 15.

PMID:
27976863
14.

Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.

Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Hasegawa H, Nomura S, Takahashi R, Yomoda S, Tsuchihara K, Kishino S, Esumi H.

Cancer Sci. 2016 Dec;107(12):1818-1824. doi: 10.1111/cas.13086. Epub 2016 Dec 19.

15.

Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.

Nguyen HX, Do TN, Le TH, Nguyen MT, Nguyen NT, Esumi H, Awale S.

J Nat Prod. 2016 Aug 26;79(8):2053-9. doi: 10.1021/acs.jnatprod.6b00381. Epub 2016 Jul 28.

PMID:
27466882
16.

Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes.

Mimaki S, Totsuka Y, Suzuki Y, Nakai C, Goto M, Kojima M, Arakawa H, Takemura S, Tanaka S, Marubashi S, Kinoshita M, Matsuda T, Shibata T, Nakagama H, Ochiai A, Kubo S, Nakamori S, Esumi H, Tsuchihara K.

Carcinogenesis. 2016 Aug;37(8):817-826. doi: 10.1093/carcin/bgw066. Epub 2016 Jun 7.

17.

Synthesis of new tricyclic thiolactams as potent antitumor agent for pancreatic cancer.

Okada T, Minehira D, Takada M, Urata H, Kato A, Adachi I, Kurashima Y, Kaji S, Ogura T, Chiba S, Esumi H, Toyooka N.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2577-9. doi: 10.1016/j.bmcl.2016.04.035. Epub 2016 Apr 16.

PMID:
27117432
18.

[Therapeutic strategies targeting cancer--specific metabolism].

Makinoshima H, Owada S, Esumi H.

Nihon Rinsho. 2015 Aug;73(8):1296-301. Review. Japanese.

PMID:
26281681
19.

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.

Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R, Goto K, Esumi H, Tsuchihara K.

J Biol Chem. 2015 Jul 10;290(28):17495-504. doi: 10.1074/jbc.M115.660498. Epub 2015 May 28.

20.

Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation.

Obata Y, Toyoshima S, Wakamatsu E, Suzuki S, Ogawa S, Esumi H, Abe R.

Nat Commun. 2014 Dec 10;5:5715. doi: 10.1038/ncomms6715.

21.

Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines.

Suzuki A, Makinoshima H, Wakaguri H, Esumi H, Sugano S, Kohno T, Tsuchihara K, Suzuki Y.

Nucleic Acids Res. 2014 Dec 16;42(22):13557-72. doi: 10.1093/nar/gku885. Epub 2014 Nov 6.

22.

Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.

Minchenko OH, Tsuchihara K, Minchenko DO, Bikfalvi A, Esumi H.

World J Gastroenterol. 2014 Oct 14;20(38):13705-17. doi: 10.3748/wjg.v20.i38.13705. Review.

23.

Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.

Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, Niho S, Yoh K, Matsumoto S, Takahashi A, Morise M, Nakamura Y, Ochiai A, Nagai K, Iwakawa R, Kohno T, Yokota J, Ohe Y, Esumi H, Tsuchihara K, Goto K.

J Thorac Oncol. 2014 Sep;9(9):1324-31. doi: 10.1097/JTO.0000000000000250.

24.

Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.

Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H, Tsuchihara K.

J Biol Chem. 2014 Jul 25;289(30):20813-23.

25.

Hypoxia imaging endoscopy equipped with laser light source from preclinical live animal study to first-in-human subject research.

Kaneko K, Yamaguchi H, Saito T, Yano T, Oono Y, Ikematsu H, Nomura S, Sato A, Kojima M, Esumi H, Ochiai A.

PLoS One. 2014 Jun 10;9(6):e99055. doi: 10.1371/journal.pone.0099055. eCollection 2014.

26.

Antiausterity activity of arctigenin enantiomers: importance of (2R,3R)-absolute configuration.

Awale S, Kato M, Dibwe DF, Li F, Miyoshi C, Esumi H, Kadota S, Tezuka Y.

Nat Prod Commun. 2014 Jan;9(1):79-82.

PMID:
24660468
27.

Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic cell-dependent NFATc1 pathways.

Yamashita T, Uehara S, Udagawa N, Li F, Kadota S, Esumi H, Kobayashi Y, Takahashi N.

PLoS One. 2014 Jan 17;9(1):e85878. doi: 10.1371/journal.pone.0085878. eCollection 2014.

28.

(+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death.

Ueda JY, Athikomkulchai S, Miyatake R, Saiki I, Esumi H, Awale S.

Drug Des Devel Ther. 2013 Dec 18;8:39-47. doi: 10.2147/DDDT.S52168. eCollection 2014.

29.
30.

Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.

Nasuno T, Mimaki S, Okamoto M, Esumi H, Tsuchihara K.

Cancer Sci. 2014 Feb;105(2):202-10. doi: 10.1111/cas.12322. Epub 2013 Dec 5.

31.

Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts.

Suzuki A, Mimaki S, Yamane Y, Kawase A, Matsushima K, Suzuki M, Goto K, Sugano S, Esumi H, Suzuki Y, Tsuchihara K.

PLoS One. 2013 Sep 12;8(9):e73484. doi: 10.1371/journal.pone.0073484. eCollection 2013.

32.

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.

Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, Goto K, Suzuki Y, Ishii G, Ochiai A, Tsuta K, Shibata T, Kohno T, Esumi H, Tsuchihara K.

Cancer Sci. 2013 Jul;104(7):896-903. doi: 10.1111/cas.12175. Epub 2013 May 12.

33.

Critical role of H2O2 generated by NOX4 during cellular response under glucose deprivation.

Owada S, Shimoda Y, Tsuchihara K, Esumi H.

PLoS One. 2013;8(3):e56628. doi: 10.1371/journal.pone.0056628. Epub 2013 Mar 21.

34.

Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry.

Kami K, Fujimori T, Sato H, Sato M, Yamamoto H, Ohashi Y, Sugiyama N, Ishihama Y, Onozuka H, Ochiai A, Esumi H, Soga T, Tomita M.

Metabolomics. 2013 Apr;9(2):444-453. Epub 2012 Nov 2.

35.

Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.

Kudou N, Taniguchi A, Sugimoto K, Matsuya Y, Kawasaki M, Toyooka N, Miyoshi C, Awale S, Dibwe DF, Esumi H, Kadota S, Tezuka Y.

Eur J Med Chem. 2013 Feb;60:76-88. doi: 10.1016/j.ejmech.2012.11.031. Epub 2012 Nov 28.

PMID:
23287053
36.

Loss of HGF activator inhibits foveolar hyperplasia induced by oxyntic atrophy without altering gastrin levels.

Yamagata Y, Aikou S, Fukushima T, Kataoka H, Seto Y, Esumi H, Kaminishi M, Goldenring JR, Nomura S.

Am J Physiol Gastrointest Liver Physiol. 2012 Dec 1;303(11):G1254-61. doi: 10.1152/ajpgi.00107.2012. Epub 2012 Oct 11.

37.

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.

Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A.

Br J Cancer. 2012 Jul 10;107(2):340-4. doi: 10.1038/bjc.2012.218. Epub 2012 May 22.

38.

An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system--a unique mitochondrial energy metabolism in tumour microenvironments.

Tomitsuka E, Kita K, Esumi H.

J Biochem. 2012 Aug;152(2):171-83. doi: 10.1093/jb/mvs041. Epub 2012 Apr 23.

PMID:
22528668
39.

Synthesis and evaluation of anticancer natural product analogues based on angelmarin: targeting the tolerance towards nutrient deprivation.

Magolan J, Adams NB, Onozuka H, Hungerford NL, Esumi H, Coster MJ.

ChemMedChem. 2012 May;7(5):766-70. doi: 10.1002/cmdc.201100564. Epub 2012 Mar 16.

PMID:
22431333
40.

Muscle-specific knock-out of NUAK family SNF1-like kinase 1 (NUAK1) prevents high fat diet-induced glucose intolerance.

Inazuka F, Sugiyama N, Tomita M, Abe T, Shioi G, Esumi H.

J Biol Chem. 2012 May 11;287(20):16379-89. doi: 10.1074/jbc.M111.302687. Epub 2012 Mar 14.

41.

Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells.

Sakai C, Tomitsuka E, Esumi H, Harada S, Kita K.

Biochim Biophys Acta. 2012 May;1820(5):643-51. doi: 10.1016/j.bbagen.2011.12.013. Epub 2011 Dec 29. Review.

PMID:
22226661
42.

Genome-wide identification and annotation of HIF-1α binding sites in two cell lines using massively parallel sequencing.

Tanimoto K, Tsuchihara K, Kanai A, Arauchi T, Esumi H, Suzuki Y, Sugano S.

Hugo J. 2010 Dec;4(1-4):35-48. doi: 10.1007/s11568-011-9150-9. Epub 2011 Feb 19.

43.

KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.

Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A.

Br J Cancer. 2011 Jul 26;105(3):403-6. doi: 10.1038/bjc.2011.247. Epub 2011 Jul 5.

44.

Identification of chrysoplenetin from Vitex negundo as a potential cytotoxic agent against PANC-1 and a panel of 39 human cancer cell lines (JFCR-39).

Awale S, Linn TZ, Li F, Tezuka Y, Myint A, Tomida A, Yamori T, Esumi H, Kadota S.

Phytother Res. 2011 Dec;25(12):1770-5. doi: 10.1002/ptr.3441. Epub 2011 Apr 6.

PMID:
21469236
45.

Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs.

Onozuka H, Tsuchihara K, Esumi H.

Cancer Sci. 2011 May;102(5):975-82. doi: 10.1111/j.1349-7006.2011.01880.x. Epub 2011 Mar 7.

46.

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.

Bando H, Tsuchihara K, Yoshino T, Kojima M, Ogasawara N, Fukushima H, Ochiai A, Ohtsu A, Esumi H.

Jpn J Clin Oncol. 2011 Feb;41(2):239-44. doi: 10.1093/jjco/hyq216. Epub 2010 Nov 26.

PMID:
21113056
47.

Measurement and verification of positron emitter nuclei generated at each treatment site by target nuclear fragment reactions in proton therapy.

Miyatake A, Nishio T, Ogino T, Saijo N, Esumi H, Uesaka M.

Med Phys. 2010 Aug;37(8):4445-55.

PMID:
20879603
48.

Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle.

Koh HJ, Toyoda T, Fujii N, Jung MM, Rathod A, Middelbeek RJ, Lessard SJ, Treebak JT, Tsuchihara K, Esumi H, Richter EA, Wojtaszewski JF, Hirshman MF, Goodyear LJ.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15541-6. doi: 10.1073/pnas.1008131107. Epub 2010 Aug 16.

49.

Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.

Ogasawara N, Bando H, Kawamoto Y, Yoshino T, Tsuchihara K, Ohtsu A, Esumi H.

Jpn J Clin Oncol. 2011 Jan;41(1):52-6. doi: 10.1093/jjco/hyq151. Epub 2010 Aug 9.

PMID:
20696815
50.

[Expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2 mRNA and its alternative splice variants in rats with experimental diabetes mellitus].

Lypova NM, Minchenko DO, Ratushna OO, Bozhko IV, Tsuchihara K, Esumi H, Minchenko OH.

Ukr Biokhim Zh (1999). 2010 Jan-Feb;82(1):90-9. Ukrainian.

PMID:
20684233

Supplemental Content

Support Center